Select therapeutic use:
Indications for GLUCOTROL XL:
Adjunct to diet and exercise in type 2 diabetes mellitus. Limitations of use: not for treating type 1 diabetes or diabetic ketoacidosis.
Limitations Of use:
Not for treating type 1 diabetes or diabetic ketoacidosis.
Swallow whole. Initially 5mg daily with breakfast. Usual range: 5–10mg once daily; max 20mg daily. Elderly, renal or hepatic impairment: initially 2.5mg. Concomitant other hypoglycemics or transferring to Glucotrol XL: see full labeling.
Type 1 diabetes, diabetic ketoacidosis, with or without coma. Sulfonamide allergy.
Increased risk of cardiovascular mortality. Adrenal or pituitary insufficiency. Stress. Secondary failure may occur with extended therapy. Risk of hemolytic anemia in G6PD deficiency; consider non-sulfonylurea alternative. Monitor urine and blood glucose. Impaired GI function or GI narrowing (XL); avoid. Discontinue if jaundice occurs or skin reactions persist. Elderly, debilitated, uncompensated strenuous exercise, malnourished or deficient caloric intake, adrenal or pituitary insufficiency, or alcohol intoxication: increased risk of hypoglycemia. Renal or hepatic impairment (see Adult). Pregnancy (Cat.C): consider using insulin instead. Nursing mothers: not recommended.
May be potentiated by concomitant oral miconazole, fluconazole, or drugs affecting glucose metabolism (eg, ACEIs, ARBs, NSAIDs, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, MAOIs, quinolones); monitor closely for hypoglycemia with co-administration and for worsening glycemic control upon withdrawal (see full labeling). May be antagonized by atypical antipsychotics, diuretics, steroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, niacin, sympathomimetics, calcium channel blockers, isoniazid, protease inhibitors; monitor. May be antagonized by colesevelam; administer glipizide ≥4hrs prior to colesevelam. β-blockers, clonidine, guanethidine, reserpine may mask hypoglycemia. Disulfiram-like reaction with alcohol (rare). Monitor for 1–2 weeks if transferring from long-acting sulfonylureas.
Sulfonylurea (2nd generation).
Hypoglycemia, tremor, asthenia, diarrhea, flatulence, allergic skin reactions, photosensitivity, blood dyscrasias, hyponatremia, dizziness, drowsiness, headache; rare: cholestatic jaundice, hepatic porphyria.
XL tabs 2.5mg—30; 5mg, 10mg—100, 500; Tabs—100